Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Brenu, Ekua W ^a   van Driel, Mieke L ^a,c   Staines, Donald R ^a,d   Ashton, Kevin J ^a   Hardcastle, Sharni L ^a   Keane, James ^a   Tajouri, Lotti ^a   Peterson, Daniel ^e   Ramos, Sandra B ^a   Marshall Gradisnik, Sonya M ^a,b  

^a BOND UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QUEENSLAND HEALTH   (Australia)

^e Sierra Internal Medicine Associates   (United States)

Author keywords

Chronic fatigue syndrome; Cytokines; Cytotoxic activity

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD; CASE-CONTROL STUDIES; CYTOKINES; FATIGUE SYNDROME, CHRONIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 84860867111     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-88     Document Type: Article

References (59)

1. Wasowska BA. Cross-talk between innate and adaptive immune responses in infection, transplant and autoimmune models. Curr Opin Organ Transplant 2011, 16:1-6. 10.1097/MOT.0b013e3283430d04, 21654356.
2. Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol 2005, 125:629-637. 10.1111/j.0022-202X.2005.23856.x, 16185260.
3. Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. Bridging innate NK cell functions with adaptive immunity. Adv Exp Med Biol 2011, 780:45-55. 10.1007/978-1-4419-5632-3_5, 21842364.
4. Gong JH, Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 1995, 181:631-640. 10.1084/jem.181.2.631, 2191888, 7836918.
5. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol 1996, 156:322-327.
6. Bochner BS, Bickel CA, Taylor ML, MacGlashan DW, Gray PW, Raport CJ, Godiska R. Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner. J Allergy Clin Immunol 1999, 103:527-532. 10.1016/S0091-6749(99)70481-1, 10069890.
7. Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O, Gray PW. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 1998, 273:1764-1768. 10.1074/jbc.273.3.1764, 9430724.
8. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010, 70:9554-9561. 10.1158/0008-5472.CAN-10-2211, 2999644, 20935224.
9. Marcenaro E, Carlomagno S, Pesce S, Chiesa MD, Parolini S, Moretta A, Sivori S. NK cells and their receptors during viral infections. Immunotherapy 2011, 3:1075-1086. 10.2217/imt.11.99, 21913830.
10. Marras F, Bozzano F, De Maria A. Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol 2011, 2011:152430. 3155793, 21860586.
11. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004, 306:1517-1519. 10.1126/science.1103478, 15567854.
12. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291. 10.1016/j.autrev.2008.08.003, 18801465.
13. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121:953-959.
14. Wallman KE, Morton AR, Goodman C, Grove R. Reliability of physiological, psychological, and cognitive variables in chronic fatigue syndrome. Res Sports Med 2005, 13:231-241. 10.1080/15438620500222562, 16392538.
15. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994, 40:601-608. 10.1111/j.1365-3083.1994.tb03511.x, 7997849.
16. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 1994, 18(Suppl 1):S136-S141.
17. Masuda A, Nozoe SI, Matsuyama T, Tanaka H. Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosom Med 1994, 56:512-518.
18. Racciatti D, Dalessandro M, Delle-Donne L, Falasca K, Zingariello P, Paganelli R, Pizzigallo E, Vecchiet J. Study of immune alterations in patients with chronic fatigue syndrome with different etiologies. Int J Immunopathol Pharmacol 2004, 17:57-62.
19. Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL. Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom 2003, 53:26-33.
20. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, Marshall-Gradisnik SM. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med 2010, 8:1. 10.1186/1479-5876-8-1, 2829521, 20064266.
21. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990, 28:1403-1410. 267940, 2166084.
22. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, Broderick G, Klimas NG. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010, 5:e10817. 10.1371/journal.pone.0010817, 2876037, 20520837.
23. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994, 18(Suppl 1):S157-S159.
24. Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 2005, 142:505-511. 1440524,1440524, 16297163.
25. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, Klimas NG, Marshall-Gradisnik SM. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011, 9:81. 10.1186/1479-5876-9-81, 3120691, 21619669.
26. Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 2004, 135:294-302. 10.1111/j.1365-2249.2004.02354.x, 1808936, 14738459.
27. Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J, de Nijs R, Bleijenberg G, Fennis JF, Miedema F, van der Meer JW. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996, 173:460-463. 10.1093/infdis/173.2.460, 8568312.
28. Metzger K, Fremont M, Roelant C, De Meirleir K. Lower frequency of IL-17 F sequence variant (His161Arg) in chronic fatigue syndrome patients. Biochem Biophys Res Commun 2008, 376:231-233. 10.1016/j.bbrc.2008.08.135, 18774769.
29. Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, Moine V, Bonnefoy JY. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 1999, 37:197-204. 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L, 10520200.
30. Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 2009, 121:294-316. 10.1016/j.pharmthera.2008.11.006, 19109992.
31. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123. 10.1001/archneur.1989.00520460115022, 2803071.
32. Klimas NG, Koneru AO. Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr Rheumatol Rep 2007, 9:482-487. 10.1007/s11926-007-0078-y, 18177602.
33. Robertson MJ, Schacterle RS, Mackin GA, Wilson SN, Bloomingdale KL, Ritz J, Komaroff AL. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol 2005, 141:326-332. 10.1111/j.1365-2249.2005.02833.x, 1809442, 15996197.
34. Saiki T, Kawai T, Morita K, Ohta M, Saito T, Rokutan K, Ban N. Identification of marker genes for differential diagnosis of chronic fatigue syndrome. Mol Med 2008, 14:599-607. 10.1007/s00894-008-0315-y, 2442021, 18596870.
35. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol 2009, Chapter 14:Unit 14 10.
36. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, Bottino C, Moretta A. Human natural killer cell receptors and co-receptors. Immunol Rev 2001, 181:203-214. 10.1034/j.1600-065X.2001.1810117.x, 11513142.
37. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223. 10.1146/annurev.immunol.19.1.197, 11244035.
38. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997, 386:514-517. 10.1038/386514a0, 9087413.
39. Scordamaglia F, Balsamo M, Scordamaglia A, Moretta A, Mingari MC, Canonica GW, Moretta L, Vitale M. Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. J Allergy Clin Immunol 2008, 121:479-485. 10.1016/j.jaci.2007.09.047, 18061653.
40. Hak L, Mysliwska J, Wieckiewicz J, Szyndler K, Trzonkowski P, Siebert J, Mysliwski A. NK cell compartment in patients with coronary heart disease. Immun Ageing 2007, 4:3. 10.1186/1742-4933-4-3, 1878503, 17488493.
41. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008, 112:1557-1569. 10.1182/blood-2008-05-078154, 2518872, 18725574.
42. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4 + CD25+ T cell suppressor function. J Immunol 2004, 172:6519-6523.
43. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006, 441:890-893. 10.1038/nature04790, 2776073, 16778891.
44. Yamane H, Zhu J, Paul WE. Independent roles for IL-2 and GATA-3 in stimulating naive CD4+ T cells to generate a Th2-inducing cytokine environment. J Exp Med 2005, 202:793-804. 10.1084/jem.20051304, 2212937, 16172258.
45. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057. 10.1182/blood-2002-09-2876, 12480696.
46. Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol 2010, 125:S53-S72. 10.1016/j.jaci.2009.07.008, 19932918.
47. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852. 10.1146/annurev.immunol.25.022106.141557, 17201677.
48. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603. 10.1084/jem.183.6.2593, 2192621, 8676080.
49. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279. 10.1084/jem.20061308, 2118116, 16982811.
50. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467. 10.1016/j.immuni.2008.03.004, 3424508, 18400188.
51. Cejas PJ, Walsh MC, Pearce EL, Han D, Harms GM, Artis D, Turka LA, Choi Y. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 2010, 115:4750-4757. 10.1182/blood-2009-09-242768, 2890173, 20351308.
52. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in Chronic Fatigue Syndrome. Brain Behav Immun 2010, In Press.
53. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96. 10.1186/1479-5876-7-96, 2779802, 19909538.
54. Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 1994, 18(Suppl 1):S147-S153.
55. Linde A, Andersson B, Svenson SB, Ahrne H, Carlsson M, Forsberg P, Hugo H, Karstorp A, Lenkei R, Lindwall A, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992, 165:994-1000. 10.1093/infdis/165.6.994, 1316417.
56. Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992, 87:76-79. 1554231, 1733640.
57. Peakman M, Deale A, Field R, Mahalingam M, Wessely S. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. Clin Immunol Immunopathol 1997, 82:83-91. 10.1006/clin.1996.4284, 9000046.
58. Gold D, Bowden R, Sixbey J, Riggs R, Katon WJ, Ashley R, Obrigewitch RM, Corey L. Chronic fatigue. A prospective clinical and virologic study. JAMA 1990, 264:48-53. 10.1001/jama.1990.03450010052029, 2162397.
59. ter Wolbeek M, van Doornen LJ, Kavelaars A, van de Putte EM, Schedlowski M, Heijnen CJ. Longitudinal analysis of pro- and anti-inflammatory cytokine production in severely fatigued adolescents. Brain Behav Immun 2007, 21:1063-1074. 10.1016/j.bbi.2007.04.007, 17544255.